Merck & Co. has finalized the $10 billion acquisition of Verona Pharma, securing the rights to its lead COPD drug, Ohtuvayre. Despite the main patent’s 2020 expiry, Merck is banking on secondary patents to maintain market exclusivity. The deal augments Merck’s portfolio in cardio-pulmonary diseases amid growing competition and signifies strategic expansion in respiratory therapeutics.